<DOC>
	<DOCNO>NCT01078558</DOCNO>
	<brief_summary>This five year , post-marketing observational study follow-up patient rheumatoid arthritis , psoriatic arthritis ankylose spondylitis treat HUMIRA ( adalimumab ) .</brief_summary>
	<brief_title>A Belgian Registry HUMIRAÂ® ( Adalimumab ) Rheumatoid Arthritis , Psoriatic Arthritis Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients ongoing HUMIRA ( adalimumab ) treatment prescribe HUMIRA ( adalimumab ) within local reimbursement guideline . Patients must willing consent data collect provided Abbott Laboratories . Contraindications accord summary product characteristic . Patients actually follow ReAlise registry ( M03634 NCT00234884 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Multicenter study</keyword>
</DOC>